National Pension Service raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 186,310 shares of the biopharmaceutical company’s stock after acquiring an additional 3,887 shares during the quarter. National Pension Service owned approximately 0.17% of Regeneron Pharmaceuticals worth $163,634,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in REGN. Everpar Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $782,000. Charles Schwab Investment Management Inc. raised its holdings in Regeneron Pharmaceuticals by 3.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 620,616 shares of the biopharmaceutical company’s stock valued at $545,081,000 after acquiring an additional 22,558 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 13.3% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 1,667 shares of the biopharmaceutical company’s stock worth $1,464,000 after purchasing an additional 196 shares during the period. Apollon Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 32.3% during the fourth quarter. Apollon Wealth Management LLC now owns 1,287 shares of the biopharmaceutical company’s stock worth $1,130,000 after purchasing an additional 314 shares during the last quarter. Finally, Lincoln National Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 49.7% during the fourth quarter. Lincoln National Corp now owns 771 shares of the biopharmaceutical company’s stock worth $677,000 after purchasing an additional 256 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 854 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $979.25, for a total transaction of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,095 shares of company stock valued at $7,779,766. 8.83% of the stock is currently owned by insiders.
Analyst Ratings Changes
Get Our Latest Analysis on REGN
Regeneron Pharmaceuticals Stock Performance
Shares of Regeneron Pharmaceuticals stock traded down $14.21 during trading hours on Wednesday, reaching $955.76. The company’s stock had a trading volume of 390,075 shares, compared to its average volume of 495,489. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The company’s 50 day simple moving average is $942.67 and its 200 day simple moving average is $899.44. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The stock has a market cap of $104.91 billion, a P/E ratio of 28.24, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- How to Choose Top Rated Stocks
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Generac Powers Ahead on the Electrification Mega-Trend
- What Are Dividend Challengers?
- PulteGroup Wins and Wins More on Interest Rate Cuts
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.